Development of a patient-reported outcome questionnaire to assess signs and symptoms of hidradenitis suppurativa: The Hidradenitis Suppurativa Symptom Diary - 14/04/23
Doi : 10.1016/j.jaad.2021.11.015
Afsaneh Alavi, MD a, Sarah Baradaran, PharmD, MS b, Susan D. Mathias, MPH c, Hilary H. Colwell, MPH c, Michael Song, MD b, Iltefat H. Hamzavi, MD d, Chenglong Han, MD, PhD b, ⁎ 
a Department of Dermatology, Mayo Clinic, Rochester, Minnesota
b Janssen Research & Development LLC, Horsham, Pennsylvania
c Health Outcomes Solutions, Winter Park, Florida
d Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
∗Correspondence to: Chenglong Han, MD, PhD, Janssen Global ServicesJanssen Global Services
Key words : health-related quality of life, hidradenitis suppurativa, HSSD, patient-reported outcomes
| Supported by Janssen Global Services, Inc. |
|
| IRB approval status: Reviewed and approved by Copernicus Institutional Review Board. |
|
| Reprints not available from the authors. |
© 2021
Publié par Elsevier Masson SAS.
Vol 88 - N° 5
P. 1123-1125 - mai 2023 Retour au numéro
Article précédent
- Acute kidney injury in vancomycin-induced drug reaction with eosinophilia and systemic symptoms: A case-control study
- Nima Milani-Nejad, John Trinidad, Benjamin H. Kaffenberger
- Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
- Soundos Youssef, Jonathan Lavian, Eunice Y. Lee, Weijia Fan, Lindsey A. Bordone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?